MRMD | Ticker Profile - Titan Protect

MRMD

MariMed Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · OQB

$0.08

Data: 2026-05-14

✗ ETHICAL FAIL

MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$34M

Total market value of the company

Trailing P/E

0.00

Forward P/E

-2.80

Based on estimated future earnings — lower means cheaper

Rev Growth

+6.9%

Year-over-year revenue change

Profit Margin

-9.1%

How much profit the company keeps from each dollar of revenue

ROE

-20.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$0.25

+229% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About MariMed Inc.

MariMed Inc. engages in cultivation, production, and selling of branded cannabis products in the United States. The company sells cannabis flower, vapes, and concentrates under the Nature's Heritage brand; and cannabis fruit chews that delivers better sleep, pain relief, stress relief, and others under Betty's Eddies brand. It offers soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; cannabis-infused hydrating drink mix for discrete and on-the-go consumption under Vibations brand; and flower, vapes, and edibles under InHouse brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is headquartered in Norwood, Massachusetts.

https://www.marimedinc.com

Country: United States Employees: 808 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

254.7% FAIL

Debt must be below 33% of total assets

Cash Ratio

26.5% PASS

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.096

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0929

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.563

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-43.2%

Historical annualised return based on price data

Max Drawdown

-76.7%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$0.23

67% below the year high

52W Low

$0.06

19% above the year low

Avg Volume

646,158

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.04

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1.32

Meaningful debt load — monitor closely

Current Ratio

0.95

Below 1 means short-term obligations exceed liquid assets — risk flag

Quick Ratio

0.27

Like current ratio but excludes inventory — stricter test

Gross Margin

36.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.3%

Profit from core operations before interest and tax

Free Cash Flow

$15M

Positive — the business generates more cash than it spends

Revenue (TTM)

$161M

Total revenue over the last 12 months

Net Income

$-12,758,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$0.25

Target Median

$0.25

Target Low

$0.25

Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date	Insider	Title	Shares	Value
2026-05-20	LEVINE JON R	Chief Executive Officer	40,000	$3,000
2026-05-07	LEVINE JON R	Chief Executive Officer	75,000	—
2026-04-02	LEVINE JON R	Chief Executive Officer	11,518	—
2026-04-02	SHAW TIMOTHY	Chief Operating Officer	9,982	—
2026-03-27	CRANDALL RYAN	Officer	6,047	—
2026-03-06	LEVINE JON R	Chief Executive Officer	23,333	—
2026-03-06	SHAW TIMOTHY	Chief Operating Officer	21,667	—
2026-03-06	CRANDALL RYAN	Officer	12,500	—
2026-02-27	SHAW TIMOTHY	Chief Operating Officer	65,000	—
2026-01-15	PINHO MARIO	Chief Financial Officer	49,995	—

Source: SEC Form 4 filings via public data. View all insider activity at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-14

Before you go